Company: HURA
Filing Date: 2025-05-23
Form Type: 424B3
Source: 0001193125-25-125499
Chunk: 413

Company: TuHURA Biosciences, Inc./NV
Filing Date: 2025-05-23
Form: 424B3
Chunk 413
---
                                                                                                                         
 inhibitors.                                                                                                                                                                                                                                                                                                                                                                                                                                                             |

| • |     | Leverage the IFx technology platform to develop next generation candidates to expand into hematologic                                                                                                                                              
 cancer indications. We are also developing IFx-3.0, its mRNA based innate immune agonist candidate, for systemic (intravenous) or autologous whole cell administration targeting the CD22 receptor on                                              
 malignant B cells as a potential treatment for blood related cancers like aggressive lymphoma, with the intention of expanding the application of IFx technology to blood related cancers not amenable to intratumoral administration. The Company 
 believes this would be the first systemically targeted mRNA innate immune agonist known to be in development.                                                                                                                                      |

| • |     | Establish a leadership position in developing immune modulating                                                                                                                                                                                        
 bi-functional ADCs and APCs. We believe that we may be the first company to identify a novel Delta Opioid Receptor that controls the regulation of multiple immune suppressive functions of MDSCs, the                                                 
 primary contributor to tumor microenvironment immunosuppression. The Company believes that inhibiting MDSC functionality may represent a novel way to overcome acquired resistance to immunotherapies. The Company believes that its immune modulating 
 bi-specific bi-functional ADCs and APCs represent a paradigm shift in this important class of therapeutics and has the potential to position the Company to take the lead on advancing these novel immunomodulatory bi-functional ADCs and APCs to     
 clinical trials.                                                                                                                                                                                                                                       |

| • |     | Establish Development and Commercial License Collaborations. Leveraging our CEO’s track record                                                                                                                    
 of successfully establishing development and commercial partnerships, we intend to seek and establish partnerships with large pharmaceutical or biotech companies as a source of non-dilutive capital and funding 
 to advance the global development of its product candidates.                                                                                                                                                      |

Cancer Immunotherapies The Cancer-Immunity Cycle For an anti-cancer immune response to lead to effective killing of cancer cells a series of stepwise events must be initiated and allowed to proceed and expand iteratively. These steps, which are illustrated in the graphic below, are 261

referred to as the “cancer-immunity cycle”. The human immune system is comprised of the innate immune system and adaptive immune system. The innate immune response, through evolution,
has developed to protect us from our surrounding environment. It is the defense system with which we are born and serves as the body’s first defense mechanism against pathogens like bacteria or viruses and alerts the immune system